Clinical Trials on Mid-face Volume Deficiency

Total 94 results

Allergan

Completed

Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency

Mid-face Volume Deficiency

Australia
Volumina Medical S.A.

Recruiting

Clinical Investigation Evaluating the Safety and Feasibility of Adipearl

Mid-face Volume Deficiency

Sweden
Laboratoires Vivacy
Avania B.V.; Canfield Scientific Inc.

Active, not recruiting

Study of STYLAGE® XXL for Volume Deficiency in the Mid-Face (MidFaceXXL)

Aging | Aesthetics | Volume Deficiency in the Mid-Face

France
Croma-Pharma GmbH
Proinnovera GmbH

Completed

THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit (TIMI)

Mid Face Volume Deficit

Austria
Allergan

Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Mid Face Volume Deficit

Canada, Spain, United Kingdom
Medy-Tox

Completed

Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-Face

Mid Face Volume Loss

China
LG Chem

Completed

To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected Into the Mid-Face

Volume Defects in the Mid-face

China
Allergan

Completed

A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula

Age-related Volume Deficit in the Mid-face

United States
Advanced Aesthetic Technologies, Inc

Recruiting

Algeness DF 3.5% Compared to Voluma in Volume Deficit in Mid-face

Age-Related Volume Deficit in the Mid-Face

Belgium, France, Germany, Israel, Malaysia, Spain, United Arab Emirates
Allergan Medical

Completed

The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face

Age-related Volume Deficit in the Mid-face

Belgium, Netherlands, Germany, United Kingdom
Laboratoires FILLMED

Completed

Evaluation of the Efficacy and Safety of Three Injectable Hyaluronic Acid-based Fillers: Art Filler® Fine Lines, Art Filler® Universal and Art Filler® Lips (AF4)

Loss of Face Volume

France
Prollenium Medical Technologies Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment

Volume Deficit in the Mid-face

Canada
Volumina Medical S.A.

Not yet recruiting

Evaluation of Safety of Filler Injection in Subcutaneous Tissues

Volume Deficiency

Switzerland
Laboratoires Vivacy

Recruiting

Study of a Novel Hyaluronic Acid Based Gel for Volume Deficiency in the Mid-face (FaceHyal) (FaceHyal)

Aging | Aesthetics | Volume Deficiency in the Mid-Face

France
Galderma R&D

Completed

A Study to Evaluate Effectiveness and Safety of Hyaluronic Acid (HA) Fillers (05DF1707)

Volume Deficiency of the Midface

Germany, Italy, United Kingdom
SciVision Biotech Inc.

Completed

The Evaluation of the Safety and Effectiveness of a Novel Gel-type Sodium Hyaluronate for the Correction of Aging Mid-face

Lidocaine | Hyaluronic Acid | Dermal Filler | Aging Mid-Face

Taiwan
SciVision Biotech Inc.

Completed

The Evaluation of the Safety and Effectiveness of ANIMERS Chiara LA and JUVÉDERM VOLUMA® for Aging Mid-Face

Lidocaine | Hyaluronic Acid | Dermal Filler | Aging Mid-Face

Taiwan
Derming SRL

Completed

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Malar and Sub-malar Volume Deficiency

Italy
Allergan

Completed

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

Mid-facial Volume Deficit Related to Aging

United States, Canada
Biopolimeri Srl
1Med

Recruiting

An Interventional Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel

Dermal Filler | Volume Deficiency of the Midface

Italy
Lifestyle Lift

Terminated

Use of V-Loc Suture for Mid-face Lifting in Short-flap Rhytidectomy

Use of the Vloc Suture | Elevation of the Mid-face

United States
Ethicon, Inc.

Terminated

A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures

Ptosis of the Neck, Mid-face and/or Jowl

Israel, France, Germany, United Kingdom
Galderma R&D

Completed

Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers (RES)

Volume Deficiency of the Midface

United States
Derming SRL

Completed

Efficacy and Tolerance Evaluation of a Bio-revitalizing Product Containing Hyaluronic Acid With High and Low Molecular Weight

Malar and Sub-malar Volume Deficiency

Italy
Galderma R&D

Active, not recruiting

A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator With a Skincare Regimen

Photodamaged Skin | Volume Deficiency of the Midface

United States
University of Turin, Italy

Completed

Effectiveness of Aligners Versus Rapid Maxillary Expansion

Maxillary Transverse Deficiency (MTD)

Italy
University of Zurich

Completed

Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women

Non Anemic Patients With Iron Deficiency (Low Ferritin Value)

Switzerland
Galderma R&D

Recruiting

Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies

Weight Loss | Skin Laxity | Photoaging | Photodamaged Skin | Volume Deficiency of the Midface

United States
University of Ulster
Queen Margaret University, Nutrition and Biological Sciences, Musselburgh... and other collaborators

Recruiting

Vitamin D in School Children (DVinCHI)

Musculoskeletal Diseases | Vitamin D Deficiency | Cognitive Delay, Mild

United Kingdom
Sandoz

Completed

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

Mild and Moderate Iron-deficiency Anaemia

Russian Federation
CSL Limited

Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID)

Australia
Michigan State University

Completed

Community Interventions to Improve Iron and Iodine Status in Mother and Child Dyads in Northern Ghana

Iron Deficiency Anemia (IDA) | Iron Deficiency (ID) | General Anemia

Ghana
University Hospital, Strasbourg, France

Completed

Severe PID With Lymphoproliferation and Neutropenia (DICEP)

Primary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)

France
Technische Universität Dresden
GWT-TUD GmbH

Completed

Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study (SIGNS)

Primary Immunodeficiency (PID) | Secondary Immunodeficiency (SID) | Neurological Autoimmune Disease

Germany
FrieslandCampina WAMCO Nigeria PLC
Lagos State University

Unknown

The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers (GaGA)

Enterobacteriaceae Infections | Nutritional Deficiency | Iron-deficiency Anemia | Nutritional Stunting | Nutritional Wasting | Malnutrition; Mild
Massimo Venturelli, PhD
University Of Perugia; University of Liverpool; INCLIVA; Molde University College; Molecular Horizon S.r.l... and other collaborators

Recruiting

Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged People (Choko-AGE)

Deficiency Diseases | Malnutrition | Dementia | Dementia, Mild | Dementia Moderate | Dementia Senile | Deficiency Nutritional

Italy
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

Hemophilia A | Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

United States, Netherlands, Belgium, France, Germany, South Africa, Spain, Canada, United Kingdom, Poland
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Recruiting

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Primary Immunodeficiency Diseases (PID)

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom

Clinical Trials on Mid-face Volume Deficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations